Cohen & Steers Q2: Rally Reflects Improving Real Estate Flows (Downgrade)
Cohen & Steers, Inc. is now rated Hold after a strong rally closed the prior valuation gap. CNS's Q2 saw net inflows of $1.3B and AUM rise to $100.1B, signaling renewed interest in public real estate. Operating margin expanded to 36.3% on revenue growth, with scope to reach 37% in H2 if markets remain stable.
Cohen & Steers, Inc. (CNS) Q2 2026 Earnings Call Transcript
Cohen & Steers, Inc. (CNS) Q2 2026 Earnings Call Transcript
Cohen & Steers Q2 Earnings Call Highlights
Cohen & Steers NYSE: CNS reported higher second-quarter 2026 adjusted earnings and assets under management, as executives pointed to improving demand for real estate, infrastructure, preferred securities and broader real assets strategies.
Cohen & Steers: Diversification From Mag 7
Cohen & Steers, Inc. (CNS) is rated BUY, driven by strong fund inflows, accelerating REIT performance, and a 37% forward P/E discount versus historical peaks. Cohen & Steers' AUM reached $93 billion in Q1 2026, with 86% of AUM outperforming benchmarks over one year and 98% over three years. REITs, comprising 48% of AUM, are benefiting from sector rotation, improved property fundamentals, and have delivered double-digit YTD returns.
Monthly Income Funds From Cohen & Steers (June Update)
Cohen & Steers, Inc. offers institutional-quality closed-end funds focused on real assets and alternative income, with a recent real estate sell-off creating attractive entry points. Fund sectors include real estate, preferred securities, infrastructure, utilities, and fixed income. C&S's expertise in alternatives, active management, and reliable monthly distributions make their CEFs excellent tools for diversification and steady income.
Axsome Therapeutics Readies Auvelity Alzheimer's Agitation Launch, Expands CNS Pipeline
Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing to launch Auvelity in Alzheimer's disease agitation this month while continuing to expand the drug's use in major depressive disorder and advance a broad central nervous system pipeline.
Cohen & Steers: Q1 Resilience Holds Fort For Q2 Recovery
Cohen & Steers, Inc. delivered resilient Q1 results despite late-quarter AUM declines driven by poor markets. CNS's focus on high-duration equity hybrids, real estate, and infrastructure makes it highly sensitive to yield curve shifts and reinflation risks. A possible enduring ceasefire and maybe normalization of shipping has CNS standing to benefit a lot, but most AMs with megacap-dominated indexed/quasi-indexed products also will benefit a lot.
Cohen & Steers: A Beneficiary Of Challenges In Private Markets
Cohen & Steers, Inc. remains a Buy, with public real estate focus and strong fund performance positioning it for renewed inflows as macro headwinds abate. CNS reported Q1 EPS of $0.79 on $144M revenue, with AUM at $93.1B and net inflows more than doubling year-over-year. Shares offer a 4.1% dividend yield, backed by a robust balance sheet and $200M in cash and treasuries, ensuring payout security.
Cohen & Steers, Inc. (CNS) Q1 2026 Earnings Call Transcript
Cohen & Steers, Inc. (CNS) Q1 2026 Earnings Call Transcript
Cohen & Steers (CNS) Moves to Buy: Rationale Behind the Upgrade
Cohen & Steers (CNS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
'Stayin' Alive' In 2026 With The Cohen & Steers Closed-End Opportunity Fund
"Stayin' Alive" worked for John Travolta in "Saturday Night Fever" and it's a worthy investment goal for me, given the economic, financial, and geopolitical risks we face in 2026. Finding a single investment that combines an attractive, well-covered yield, solid multi-year total returns, quality management, and significant diversification is not easy. But Cohen & Steers' Closed End Opportunity Fund comes really close to filling the bill; I've described it previously as an "instant Income Factory"
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots
Ovid Therapeutics targets neuronal hyperexcitability with two small-molecule platforms. 1) OV329 (GABA-AT inhibition) and 2) KCC2 direct activators for neuropsychiatric disorders. OV329 Phase 2a in drug-resistant focal seizures is planned for Q2 2026. And we should get its topline data by mid-2027. OVID's KCC2 program leads with OV4071, which targets PD/LBD psychosis and schizophrenia. Its IND is expected by Q1 2026, and its Phase 1 by Q2 2026.
